NCT00806351

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.

Conditions

• Fungemia
• Neutropenia
• Candidiasis

Interventions

Type	Name	Description
DRUG	Active Anidulafungin	Subjects in this arm will receive active anidulafungin and placebo caspofungin
DRUG	Active Caspofungin	Subjects in this arm will receive active caspofungin and placebo anidulafungin

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2008-12-10
• Last updated: 2012-12-20
• Results posted: 2012-12-20

Locations

10 sites across 6 countries: Bosnia and Herzegovina, France, Italy, Poland, Russia, Slovakia